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other interferons were less potent. The activation of JAK 
kinase by IFNβ, as suggested by bioinformatics analysis of 
the transcriptome changes, was confirmed by biochemical 
methods. The degree and duration of pathway activation 
correlated with the extent of migration inhibition, and phar-
macological block of this signaling pathway before, or up 
to 6 h after exposure to the cytokine prevented the effects 
of IFNβ on migration. Thus, the reduction of vital func-
tions of human NCC is a hitherto unknown potential hazard 
of endogenous or pharmacologically applied interferons.
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Abstract Human cell-based toxicological assays have 
been used successfully to detect known toxicants, and to 
distinguish them from negative controls. However, there is 
at present little experience on how to deal with hits from 
screens of compounds with yet unknown hazard. As a case 
study to this issue, we characterized human interferon-beta 
(IFNβ) as potential developmental toxicant affecting neural 
crest cells (NCC). The protein was identified as a hit during 
a screen of clinically used drugs in the ‘migration inhibi-
tion of neural crest’ (MINC) assay. Concentration–response 
studies in the MINC combined with immunocytochemistry 
and mRNA quantification of cellular markers showed that 
IFNβ inhibited NCC migration at concentrations as low 
as 20 pM. The effective concentrations found here corre-
spond to levels found in human plasma, and they were nei-
ther cytostatic nor cytotoxic nor did they did they affect the 
differentiation state and overall phenotype of NCC. Data 
from two other migration assays confirmed that picomolar 
concentration of IFNβ reduced the motility of NCC, while 
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Introduction
Any kind of external interference which alters the spatio-
temporal organization of development can lead to develop-
mental defects (Smirnova et al. 2014; Aschner et al. 2017). 
Where protein signals are involved in the fine-tuning of cell 
and organ development, antigenic properties and recep-
tor affinities play an important role. As these factors are 
often species-specific, the developmental hazard, and many 
other side effects of cytokines, antibodies and blood fac-
tors are difficult to assess in animal models. As alternative 
approach, human cell-based test systems have been devel-
oped and they play an increasingly important role in drug 
development.
The approach of using in vitro tests is based on the strat-
egy that a battery of assays may be assembled that cov-
ers the majority of fundamental developmental processes 
(Leist et  al. 2014; Smirnova et  al. 2014; Schmidt et  al. 
2016). These include, for instance, neural differentiation 
(Zimmer et  al. 2011b; Balmer et  al. 2012), neurite out-
growth (Stiegler et al. 2011; Krug et al. 2013a), gliogenesis 
(Fritsche et al. 2005; Kleiderman et al. 2016), myelination 
(Zurich et al. 2000, 2002), or synaptogenesis (Harrill et al. 
2011).
In this context, the migration inhibition of neural crest 
cells (MINC) assay was developed as the first method 
to test effects of toxicants on the function of the neu-
ral crest (NC) during development (Zimmer et  al. 2012; 
Dreser et al. 2015). The importance of this developmen-
tal stage justified the inclusion of the MINC assay in the 
in vitro test battery of the European research consortium 
ESNATS (Embryonic Stem cell-based Novel Alternative 
Testing Strategies) (Zimmer et  al. 2014). The NC is a 
multipotent migratory cell population that emerges from 
the dorsal aspect of the neural tube in the early phases of 
development. NC cells (NCC) are capable of long range 
migration, which is finely regulated in the embryo. Dur-
ing migration, and at the final destination, NCC give rise 
to a multitude of different cell types, supporting the for-
mation of cartilage and bone of the face, but also periph-
eral and enteric neurons, melanocytes, and some cardio-
myocytes (Huang and Saint-Jeannet 2004).
A large percentage of developmental disorders (e.g., con-
genital heart defects, oro-facial clefts, and Hirschsprung’s 
disease) are caused by NCC deficits (Simões-Costa and 
Bronner 2013), and these often correlate with neural tube 
defects. Such alterations can be induced by genetic factors 
(Lee et al. 2009) or exposure to pharmaceuticals (e.g., valp-
roic acid) (Fuller et al. 2002) and pesticides (e.g., triadime-
fon) (Menegola et al. 2000).
The MINC assay has been used to screen and evaluate 
the effects of many different compounds on neural crest 
function (Zimmer et  al. 2012, 2014; Dreser et  al. 2015). 
In addition to known environmental toxicants, the screen-
ing identified some drug-like compounds as hits, and these 
included the type I interferon IFNβ (Zimmer et al. 2014). 
The developmental toxicity of IFNβ has been evaluated 
in cynomolgus monkeys, where an increased incidence of 
both abortions and stillbirths was observed (FDA 1999). 
Furthermore, epidemiological studies indicated that expo-
sure to IFNβ in pregnancy is associated with lower mean 
birth weight, and preterm birth (Amato et  al. 2010). For 
these reasons, women with MS are typically advised to dis-
continue the treatment before conceiving. IFNβ is classified 
as risk class C drug by the FDA, indicating that “animal 
reproduction studies have shown an adverse effect on the 
fetus and there are no adequate and well-controlled stud-
ies in humans, but potential benefits may warrant the use of 
the drug in pregnant women despite the potential risks” (Lu 
et al. 2012; Pozzilli and Pugliatti 2015).
The interferon family is clinically used for different pur-
poses, as interferons have a crucial role in the anti-viral 
cell response, and in modulating several functions of the 
immune system. Type I interferons comprise IFNα and 
IFNβ. All type I IFNs bind the interferon alpha and beta 
receptor (IFNAR) subunits and produce structurally highly 
similar receptor-ligand complexes (Schreiber and Piehler 
2015). While IFNα is mainly used for treatment of cer-
tain types of leukemia and hepatitis virus infections, the 
immunomodulatory drug IFNβ has proven effective in the 
treatment of relapsing-remitting multiple sclerosis (MS) 
(Dhib-Jalbut and Marks 2010). The mode of action of the 
latter cytokine is still not fully understood, but it induces an 
anti-inflammatory cytokine shift and prevents T-cell adhe-
sion and extravasation across the blood–brain barrier. The 
type II interferon IFNγ binds to different receptors and has 
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pronounced inflammatory and immune-stimulating proper-
ties (Schroder et al. 2004).
While elaborate strategies have been established for hit 
follow-up of drug discovery screens, such concepts still 
need to be developed for toxicological high-throughput 
testing. For statistical, strategic, and technical reasons, 
large screens have a high propensity to yield false-posi-
tives. Two approaches have proven useful in drug discov-
ery: (1) follow-up of screen results under non-screen condi-
tions (new compounds, new cells, low throughput, and low 
time constraint to allow stringent controls of each step), 
first with the original assay, then with secondary and ter-
tiary tests; (2) exploration around the hit findings (use of 
related compounds; exploration of mechanistic and tem-
poral consistency) to provide biological plausibility and a 
more robust data base. Such a strategy was explored in the 
present study to further substantiate or refute a potential 
developmental toxicity hazard of IFNβ. The adverse effects 
of IFNβ on NCC migration and proliferation were studied 
in three different assays. Additional analysis of transcrip-
tome changes was performed, and the JAK-STAT signaling 
pathway was considered as a mediator of toxicity. The role 
of the pathway in a potential hazard of IFNβ was confirmed 
by detailed measurements of interferon effects on signal-
ing and cell function in the presence of specific kinase 
inhibitors.
Materials and methods
Cell culture and neural crest differentiation
The reporter human embryonic stem cell line H9-Dll1 
(GFP under Dll1 promoter) was provided by Mark Tom-
ishima from the Memorial Sloan Kettering Cancer Centre 
(MSKCC, NY, USA). Import of the cells and all experi-
ments was carried out according to German legislation 
under the license number 1710-79-1-4-27 of the Robert-
Koch Institute.
H9-Dll1 cells were maintained on mouse embryonic 
fibroblasts in DMEM/F12 (Gibco™, Carlsbad, CA, USA) 
medium containing 20% of serum replacement (Knock-
out SR, Gibco™), HEPES (Gibco™), L-gluthamine (Glu-
tamax, Gibco™), non-essential amino acids (MEM NEAA, 
Gibco™), beta-mercaptoethanol (Gibco™), and basic 
fibroblast growth factor (10 ng/ml, Invitrogen™, Carlsbad, 
CA, USA).
Differentiation of hESC into NCC was initiated on mito-
mycin C (Sigma–Aldrich©, St. Louis, MO, USA) treated 
murine bone-marrow derived stromal MS5 cells and con-
tinued in N2 medium exactly as described previously (Zim-
mer et al. 2012).
The human breast adenocarcinoma cell line MDA-
MB-231 (ATCC HTB-26™) was maintained in DMEM 
Glutamax (Gibco™) containing 10% FCS (Invitrogen) and 
1% penicillin/streptomycin.
Cell culture quality control
Cell culture experiments were performed according to 
GCCP (good cell culture practice) principles. All cell lines 
were regularly tested for mycoplasma contamination by the 
use of commercial kits (Venor Gem, Minerva Biolabs).
Identity of the used cell types was confirmed by STR 
(Short Tandem Repeat) analysis. Briefly, DNA samples 
from the H9 (NIH registry name WA09) and H9-Dll1 cell 
lines were prepared using a commercial kit (Puregene Cell 
Kit, Qiagen). The kit  GlobalFiler® PCR Amplification Kit 
(Thermofisher) was then used to determine the cell-spe-
cific profile for 16 different genomic loci using an Applied 
Biosystems GeneMapper Device. STR results showed 
100% identity of the profiles of H9 and H9-Dll1, and these 
matched 100% the literature reference data (Josephson 
et al. 2006) (suppl. Fig S1).
Interferon exposure during NCC migration
NCC were exposed for 48  h to non-cytotoxic concentra-
tion of different interferons (recombinant human IFN-
beta 1a, recombinant human IFN-alpha 2a, recombinant 
human IFN-gamma) in N2 medium containing human EGF 
(20 ng/ml) and FGF2 (20 ng/ml) (all from R&D Systems 
 GmbH®, Minneapolis, MN, USA). Interferon stock solu-
tions were prepared in 0.1% BSA in PBS at concentrations 
of 200 nM and 10  µM, respectively, for IFN-beta 1a and 
IFN-alpha 2a. We assumed the nominal drug concentra-
tions indicated in the figures/tables to correspond closely to 
the actual free concentrations, as protein binding of IFNβ 
is low (<10%). However, some absorption to the cell cul-
ture plastic might have occurred. Where indicated, cytosine 
arabinoside (AraC, Sigma) or JAK inhibitors (Ruxolitinib 
and Tofacitinib, Selleckchem©, Munich, Germany) were 
added. The migration assay was performed as described 
previously (Nyffeler et  al. 2016). Briefly, NCC cells were 
seeded (95,000 cells/cm2) in 96-well plates (Corning©, 
NY, USA) previously coated with 10 µg/ml poly-l-ornith-
ine in 100 µl phosphate buffered saline (PBS) (GE Health-
care Bio-Sciences©, Pittsburgh, PA, USA) and 1  µg/ml 
fibronectin and 1 µg/ml laminin (Sigma–Aldrich) in 100 µl 
PBS. Cells were seeded in the presence of silicon stop-
pers (Platypus Technologies, Madison, WI, USA) to create 
a circular cell-free area. One day after seeding, migration 
into the cell-free area was initiated by manual removal of 
the stoppers and the medium was replaced with medium 
containing the test compounds. After 48  h, NCC were 
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stained with 1 µg/ml H-33342 (nuclei) and 533 nM calcein-
AM (to stain the outline of viable cells) (Sigma–Aldrich) 
and imaged 30 min later on a high content imaging micro-
scope (Cellomics ArrayScanVTI, Thermo Fischer©, Bos-
ton, MA, USA).
Viability was defined as the number of H-33342 and cal-
cein double-positive cells, as determined by an automated 
algorithm described earlier (Stiegler et al. 2011; Krug et al. 
2013b). For quantification of migration, a software tool 
(freely accessible at http://invitrotox.uni-konstanz.de/) was 
developed to estimate the most likely position of the previ-
ously cell-free area (covered by the silicon stopper), to set 
thresholds for color intensity for both dyes, and to count the 
number of H-33342 and calcein double-positive cells in the 
region of interest.
EdU staining
Cells were treated for 48 h with 10 µM 5-ethynyl-deoxyu-
ridine (EdU). Proliferating cells incorporate EdU and can 
be detected using a click reaction procedure, as described 
in the manufacturer’s protocol (EdU-Click 555, PanaTecs, 
Heilbronn, Germany). Images were acquired using a high 
content imaging microscope (Cell Insight Personal Imager, 
Thermo Fisher©). Proliferation was defined as the percent-
age of EdU-positive nuclei among all H-33342 positive 
nuclei.
Immunofluorescence staining
Cells were seeded in  Lumox® multiwell plates (95,000 
cells/cm2). After 42-h treatment, the middle of the well was 
scratched with a pipette tip to create a cell-free space in the 
well and cells were allowed to migrate for 6 h in presence 
of the treatment. Finally, the cells were fixed in 4% PFA 
for immunofluorescence staining. Cells were permeabi-
lized for 10 min in 0.2% Triton and blocked with 10% FBS 
for 1  h. Afterwards, cells were incubated overnight with 
primary antibody (GM130, Abcam©, Cambridge, UK; 
TOM20, Santa Cruz Biotechnology™, Santa Cruz, CA, 
USA) or Alexa Fluor 555 phalloidin diluted in 4% FBS. 
After a washing step, the secondary antibody was applied 
for 1  h. Cell nuclei were finally stained with H-33342. 
Images were acquired mainly from the scratch area (to cap-
ture migrating cells at a density typically also found in the 
standard cMINC assay setup) using a point laser scanning 
confocal microscope Zeiss LSM 700 (Zeiss©, Oberkochen, 
Germany).
Western blot
Cells were seeded in 6-well plates (50,000 cells/cm2); 
after 24 h, cells were treated for the indicated times. Cells 
were then harvested in Laemmli buffer, boiled for 5  min 
at 95 °C and purified with the NucleoSpin Filters (Mach-
erey–Nagel GmbH, Düren, Germany). Samples were run 
on SDS–PAGE. Transfer on nitrocellulose membranes was 
performed by using iBlot™ 2 Dry Blotting System (Inv-
itrogen). Membranes were then incubated in 5% milk in 
T-TBS for 1 h and overnight with the primary antibody in 
5% BSA in T-TBS at 4 °C (p-STAT1 Y701, Cell signaling 
technology). After washing steps, membranes were incu-
bated with secondary antibody conjugated with horseradish 
peroxidase (GE Healthcare Bio-Sciences©) for 1 h at room 
temperature. Signal was finally detected using Pierce ECL 
wester blotting substrate (Thermo Scientific© Boston, MA, 
USA) and imaged with a Fusion-SL 3500 WL device and 
Fusion software (Bio-Rad™, Hercules, CA, USA). After-
wards, the membrane was further incubated for 3  h with 
the primary antibody specific for the housekeeping protein 
GAPDH (Invitrogen). The same procedure as described 
above was followed for detection and imaging of the house-
keeping signal.
NFkB translocation
Cells were stimulated by a cytokine mix (CM) containing 
10 ng/ml tumor necrosis factor α (TNFα), 10 ng/ml inter-
leukin 1β (IL-1 β), and 20  ng/mL IFNγ (R&D Systems, 
Wiesbaden, Germany) or with 500 pM IFNβ for 1 h. For 
NFkB measurement, cells were fixed, permeabilized, and 
stained with NFkB antibody (Santa Cruz Biotechnol-
ogy™). NFkB translocation was measured with the high-
throughput device CellInsight TM CX5 High Content 
Screening (Thermo Scientific©) using the nuclear trans-
location algorithm as described previously (Henn et  al. 
2011).
Cell tracking
Live cell imaging was performed using an Axio Observer. 
Z1 microscope (Zeiss©) equipped with an incubation sys-
tem (37 °C, 5%  CO2) and the software Zen2. Cells were 
imaged for a period of 48 h, taking phase contrast pictures 
every 15 min with a 5x objective. Images of the last 30 h 
migration period were loaded in Fiji ImageJ and manually 
tracked with the plugin “Manual track” Schindelin et  al. 
(2012). The tracked positions were then loaded into the 
freely available “Chemotaxis and Migration Tool” (Ibidi) 
to calculate the total distance and the cell speed as well as 
to create the track pictures.
Transwell assay
Cells were treated for 42  h and then detached by using 
Accutase (Corning©), counted and seeded (50,000 cells/
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transwell) in upper chamber of previously coated Transwell 
Permeable Support plates (0.8  µm polycarbonate mem-
brane, Costar, Corning©) in normal medium with addi-
tion of IFNβ (500 pM) or respective control. Ten percent 
FBS in normal medium was added in the lower chamber 
of the transwell. After 6 h of incubation at 37 °C, cells at 
the upper side of the membrane were removed and the cells 
attached to the lower side of the membrane were fixed and 
stained with crystal violet for 30  min, and then washed 
in current water and let dry. Cells were imaged with light 
microscope Axio Observer.Z1 microscope (Zeiss©) using 
the software PALM RoboSoftware (4 fields per condition, 
20× magnification) and manually counted in ImageJ.
Affymetrix gene chip analysis
Samples of ≥5 × 106 cells were collected using RNA pro-
tect reagent from Qiagen. The RNA was quantified using 
a NanoDrop N-1000 spectrophotometer (NanoDrop, Wilm-
ington, DE, USA), and the integrity of RNA was confirmed 
with a standard sense automated gel electrophoresis system 
(Experion, Bio-Rad™, Hercules, CA, USA). Analysis was 
then performed as described earlier (Krug et  al. 2013b) 
using Affymetrix chip-based DNA microarray (Human 
genome U133 plus 2.0 arrays) with all standard quality 
control procedures. The raw CEL files and secondary Affy-
metrix chip data have been deposited in the GEO database 
according to the MIME rules, with the accession number 
GSE94521. The differentially expressed probe sets for 
each compound including fold changes and p values of the 
limma t test are given in supplementary tables provided in 
an Excel file format (supplemental Table 1; Fig S3).
Biostatistics
The microarray data analysis (extrapolation and normali-
zation of the array sets) was performed using the statisti-
cal programming language R (version 3.1.1) as described 
previously (Waldmann et al. 2014). For the normalization 
of the entire set of Affymetrix gene expression arrays, the 
Extrapolation Strategy (RMA+) algorithm (Harbron et al. 
2007) was used that applies background correction,  log2 
transformation, quantile normalization, and a linear model 
fit to the normalized data to obtain a value for each probe 
set (PS) on each array. As reference, the normalization 
parameters obtained in earlier analyzes (Krug et al. 2013b) 
were used. After normalization, the difference between 
gene expression and corresponding controls was calculated 
(paired design). Differential expression was calculated 
using the R package ‘limma’ (Smyth et  al. 2005). Here, 
the combined information of the complete set of genes is 
used by an empirical Bayes adjustment of the variance esti-
mates of single genes. This form of a moderated t test is 
abbreviated here as ‘Limma t test’. The resulting p values 
were multiplicity-adjusted to control the false discovery 
rate (FDR) by the Benjamini–Hochberg procedure (Ben-
jamini 1995). As a result, for each compound, a gene list 
was obtained, with corresponding estimates for log-fold 
changes and p values of the Limma t test (unadjusted and 
FDR adjusted).
Transcripts with FDR adjusted p values of ≤0.05 and 
fold change values of ≥1.8 or ≤0.55 were considered sig-
nificantly deregulated and defined as differential expressed 
genes (DEG).
Data display: heat map and principal component 
analysis
The software R (version 3.1.1), was used for all calcula-
tions and display of principal component analysis (PCA) 
and heatmaps. PCA plots were used to visualize expression 
data in two dimensions, representing the first two principal 
components. The percentages of the variances covered are 
indicated in the figures.
Gene ontology (GO) and KEGG pathway enrichment 
analysis
The gene ontology group enrichment was performed using 
R (version 3.1.1) with the topGO package (Alexa et  al. 
2006) using Fisher’s exact test, and only results from the 
biological process ontology were kept. Here, again, the 
resulting p values were corrected for multiple testing by the 
method of Benjamini–Hochberg (Benjamini 1995).
The KEGG pathway analysis was performed using the R 
package “hgu133plus2.db” (Carlson 2015). Probesets were 
mapped to the identifiers used by KEGG for pathways in 
which the genes represented by the probesets are involved. 
The enrichment was then performed analogous to the gene 
ontology group enrichment using Fisher’s exact test.
Up- and down-regulated differentially expressed 
genes were analyzed separately for each treatment. Only 
GO classes and KEGG pathways with a BH (Benja-
mini–Hochberg)-adj. p values ≤0.05 were considered 
significant.
GO superordinate classes distribution
Enriched GOs were then assigned to superordinate cell bio-
logical processes as already described previously (Wald-
mann et al. 2014) and distributed in six classes: migration/
adhesion, metabolism, differentiation, signaling, stress 
response, and others. The migration class includes migra-
tion and adhesion-related-GO classes; stress response class 
includes cell death-, extracellular stressor-, and inflamma-
tion/immunity-related GO classes; signaling class consists 
 Arch Toxicol
1 3
of cell receptor activity-, second messenger (cAMP, cGMP, 
Ca2+) metabolism-, and kinase modification-related GO 
classes. Metabolism class comprises all GO classes cover-
ing metabolism activity; differentiation class includes cell 
differentiation related- GO classes; and; “other” class cov-
ers the others not otherwise classified GO classes.
Quantitative PCR (qPCR) analysis
Cells were seeded in 6-well plates (50,000 cells/cm²); 
after 24 h, cells were treated for 48 h. Cells were then har-
vested and lysed in PeqGOLD Trifast™ (PEQlab©, Erlan-
gen, Germany). Total RNA was isolated by phenol–chlo-
roform extraction. Reverse transcription was performed 
using 1 µg RNA and the i-Script™ Reverse Transcription 
Supermix (Bio-Rad™) according to the manufacturer’s 
protocol. Quantitative real-time PCR was performed with 
SsoFast EvaGreen Supermix (Bio-Rad™) using a CFX96 
Real-Time PCR Detection System (Bio-Rad™). The 
primer sequences are reported in the supplementary mate-
rial (suppl. Fig S2). The cycle threshold values were deter-
mined using the Bio-Rad CFX Manager Software v2.0 
(Bio-Rad™). Results were analyzed using the ΔCt method 
(Livak and Schmittgen 2001) and normalization for house-
keeping genes exactly as described earlier (Zimmer et  al. 
2011a, b; Weng et al. 2012, 2014).
Results
Specific effects of IFNβ on human neural crest cell 
(NCC) migration
In a previous study (Zimmer et al. 2014), IFNβ was found 
as a positive hit in a screen of drugs for potential develop-
mental toxicity in human NCC. To confirm the effects of 
the cytokine IFNβ on human NCC migration, a new auto-
mated and operator-independent test method (Nyffeler et al. 
2016) was used. NCC, generated from pluripotent stem 
cells, were allowed to migrate in the presence or absence of 
IFNβ for 48 h (Fig. 1a). Picomolar concentrations of IFNβ 
induced a significant inhibition of migration (Fig. 1b, left 
graph), as indicated by the reduced number of cells found 
in the migration zone (Fig. 1c). The migration capacity was 
reduced to 75% at 20 pM (Fig.  1b, left graph), but IFNβ 
also affected the cell viability endpoint at this concentration 
(reduction of the cell number by ~16%, p value <0.01). As 
no dead or dying cells were observed at any time point, the 
apparent ‘reduction of viability’ was most likely due to the 
known cytostatic effect of the cytokine (Bekisz et al. 2010).
For interpretation of the data from the MINC assay used 
here, it is important background information that NCC 
still proliferate during the assay. Thus, it is possible that 
drugs that inhibit proliferation, but not migration, show a 
false positive effect in the assay. Indeed, clear cell cycle 
inhibitors, like the DNA synthesis inhibitor aphidicolin, 
have been found to reduce the number of cells found in 
the migration area at the end of the experiment (Nyffeler 
et al. 2016). To exclude any effect on proliferation, we used 
the mitosis inhibitor cytosine arabinoside (AraC, 10  µM) 
as cell medium additive. Under such test conditions, any 
proliferation was blocked (Fig. 1d), and the specific effect 
of cytostatic drugs on migration can be quantified with-
out interference of cell cycle effects. When the assay was 
repeated in the presence of AraC, IFNβ did not affect the 
viability endpoint at all, but it still triggered a significant 
inhibition of migration at 25 pM, and the threshold of 25% 
reduction (Zimmer et al. 2012, 2014; Nyffeler et al. 2016) 
was reached at 50 pM (Fig.  1b, right graph). Thus, data 
from different test formats corroborated the earlier finding 
that pM concentrations of IFNβ reduced the migration of 
NCC, independent of any potential effects of the drug on 
NCC proliferation.
To investigate whether the effects observed were specific 
for IFNβ within the interferon family, related cytokines 
were also tested: IFNα and IFNγ. IFNα binds to the same 
receptor as IFNβ, but with lower affinity. Accordingly, it 
affected migration only at much higher (two orders of mag-
nitude) concentrations (Fig. 2a). In contrast to this, the type 
II interferon IFNγ affected viability and the migration end-
point at low pM concentrations, similar to IFNβ (Fig. 2b). 
To unambiguously separate the effects on proliferation 
from those on migration, the interferons were tested under 
non-proliferating assay conditions (Fig. 2a, b), and both the 
75% effective concentration (EC75) as well as the lowest 
effective concentration (LOAEL) were determined for the 
migration endpoint and compared to IFNβ (Fig. 3c). These 
experiments showed that IFNα inhibits migration of NCC, 
but that it was about two orders of magnitude less potent. 
The data also showed that IFNγ mainly affected the NCC 
proliferation at low pM concentration, while specific effects 
of migration were only observed in the nM range. Thus, 
IFNβ is the only tested interferon that affected the migra-
tion of NCC at clinically relevant low pM concentrations.
As migration is a fundamental cell biological process, it 
may be assumed that the capacity of IFNβ to disturb cell 
movement may apply to many other cell types. However, it 
was shown earlier that many toxicants affect NCC migra-
tion without affecting, for example, tumor cells or other 
neural precursors (Zimmer et al. 2012). To study such spec-
ificity for IFNβ, we used the human breast cancer cell line 
MDA-MD-231, which is highly metastatic, displays a mes-
enchymal/fibroblastoid phenotype (Prat et  al. 2010), and 
thus migrates in a somewhat similar way as NCC. Under 
proliferating conditions, IFNβ showed potent effects (low 
pM range) on both the migration and the viability endpoints 
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(Fig. 2d, left graph). Under test conditions that avoided any 
drug effects on proliferation, no inhibition of migration by 
IFNβ was detected (Fig. 2d, right graph). Thus, the effect 
of IFNβ on the migration of cells did not apply to any cell 
type, but may be rather specific for NCC.
Maintenance of basic functions and cell morphology 
after exposure to IFNβ
One straightforward explanation for the relatively specific 
effects of IFNβ on NCC migration may be a change of 
the cell differentiation state by the cytokine. For instance, 
a mesenchymal-to-epithelial (MTE) transition or a dif-
ferentiation to a neural or other final cell type may reduce 
spontaneous migration of the cells. Therefore, various 
cell features were studied. We examined several typical 
cell type-specific mRNA markers (e.g., MSX1, SOX9, 
SNAIL2, NRP1, and PAX3), and none of them changed 
their expression level upon exposure to IFNβ (suppl. Fig. 
S4). Moreover, the characteristic cell shape was main-
tained. To assess the latter finding in more detail, some 
molecular markers of cell structure were studied. NCC 
were treated with a maximal concentration of IFNβ (500 
pM) for 48 h. Then, the F-actin microfilaments were visual-
ized with phalloidin. Mitochondrial structures were stained 
with an antibody to TOM20, and the Golgi apparatus was 
stained for the GM130 protein. Multiple images (>15) were 
recorded for each conditions, and two observes blinded to 
Fig. 1  Impaired migration of NCC in the presence of IFNβ. a NCC 
were allowed to attach and recover for 24  h. Then, migration was 
started and, 48 h later, the number of migrated cells and the viabil-
ity of the cell population were quantified. In standard experiments, 
NCC were exposed to IFNβ (marked in green) for the entire migra-
tion period. b NCC were exposed to IFNβ at the indicated concentra-
tions. Cell viability and the number of migrated cells are expressed 
relative to control cells (Ctrl, 0.1% BSA in PBS). In one series of 
experiments (right graph), the cell culture medium used for all condi-
tions was supplemented with the mitosis inhibitor cytosine arabino-
side (AraC, 10  µM). Data are from three independent experiments. 
Error bars indicate standard deviations (SD). Statistics was per-
formed for each endpoint by ANOVA, followed by Dunnet’s post-hoc 
test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). Viability was considered to 
be impaired when it dropped below 90%; migration was considered 
to be impaired below 75%, compared to control (dotted lines at 75 
and 90% are indicated for visual support). c Representative pictures 
of different migration assay exposure scenarios, taken at time 48  h. 
Nuclei are depicted in red (H-33342), while viable cells are shown 
in green (calcein). d NCC were exposed to culture medium supple-
mented with 5-ethynyl-2′-deoxyuridine (EdU, 10 µM) and they were 
treated with AraC (10 µM) or the respective control (Ctrl) for 48 h. 
Then, cells were stained with H-33342 (nuclei), and EdU-positive 
cells (EdU+) were quantified. Cell proliferation was expressed as per-




the treatment condition examined the cell features. No dif-
ferences were observed that could be related to the treat-
ment with IFNβ (Fig. 3a).
In a next step, various functions associated with cell 
adhesion were studied. The expression of 20 integrins and 
cadherins was studied, and none of them changed >30% in 
the presence of IFNβ (suppl. Fig. S5). In a more functional 
approach, we assessed the phosphorylation (and activation) 
level of the focal adhesion kinase (FAK). Protein samples 
were prepared from NCC after 0, 6, or 24 h of adhesion, 
either with or without IFNβ (500 pM). Adhesion of the 
cells led to the activation of FAK, as expected. This pro-
cess was not significantly affected by exposure to IFNβ 
(Fig. 3b).
In a third approach, we examined whether IFNβ may 
affect the response of cells to external stimuli, such as 
mitogenic or inflammatory cytokines. NCC were incubated 
without the growth factors EGF/FGF overnight, and then 
exposed to these cytokines in the presence of absence of 
IFNβ. IFNβ alone neither triggered the MAP kinase path-
ways (as measured by phosphorylation of Erk) nor the Akt 
pathway (as measured by phosporylation of Akt). EGF/FGF 
clearly triggered these pathways and this effect was not 
affected by IFNβ (suppl. Fig. S6). Alternatively, NCC were 
exposed to inflammatory cytokines (CM: TNFα and IL1β) 
to probe the response of the NFkB pathway. The CM trig-
gered translocation of the transcription factor NFkB from 
the cytosol to the nuclei (Fig. 3c, upper panels) in 91 ± 7% 
of all cells. IFNβ itself did not trigger NFkB translocation. 
Neither did it affect the signaling of the CM. (Fig. 3c, lower 
right panel). Thus, no obvious structural features and none 
of the tested signaling functions were impaired by exposure 
to IFNβ.
Attenuation of NCC migration speed and chemotactic 
behaviour by IFNβ
To confirm the impairment of NCC migration by IFNβ, and 
to further exclude any artefacts due to drug effects on cell 
proliferation or differentiation, two other functional assays 
were used. The first approach made use of time lapse imag-
ing and cell tracking to study effects on cell speed. Migrat-
ing cells were incubated with IFNβ on a microscope stage 
in a temperature-controlled incubation system (Fig.  4a). 
This setup allowed a continuous recording of phase con-
trast images for 30 h. The image stacks were then used to 
track the migrating cells (≥10 cells per well) (Fig.  4b). 
Analysis of the tracks revealed a concentration-dependent 
reduction of the accumulated distance travelled by IFNβ-
treated NCC, compared to control cells (Fig.  4c). Thus, 
this method confirmed on the single cell level that IFNβ 
reduced the migration speed.
Fig. 2  Specificity of IFNβ effects on NCC. NCC were treated for 
48  h with interferons, while they were allowed to migrate. Then, 
the viability and the inhibition of cell migration were measured. 
All assays were performed either with or without cytosine arabino-
side (AraC, 10 µM) as culture medium supplement. a, b Testing of 
interferon-α (IFNα) and interferon-γ (IFNγ). Data are from three 
independent experiments. Error bars indicate standard deviations 
(SD). Statistics was performed for each endpoint by ANOVA, fol-
lowed by Dunnet’s post-hoc test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). 
c  EC75 and the lowest observed adverse effect level (LOAEL) were 
compiled for each scenario. The LOAEL was defined as the low-
est concentration triggering a significant reduction of cell migration 
(p ≤ 0.05). d Human breast cancer cells MDA-MD-231 were allowed 
to migrate for 48 h, before viability and the number of migrated cells 
were quantified. Cells were treated with the indicated concentrations 
of IFNβ for the total migration period, either with or without cytosine 
arabinoside (AraC, 10 µM) as culture medium supplement
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The second approach made use of a transwell set-up. In 
this system, cells can be seeded onto a porous membrane 
in the upper compartment. When a chemoattractant (here 
FBS was used) is added to the bottom part, cells are trig-
gered to migrate through the membrane. NCC were seeded 
on the transwell membrane directly or after a 42-h pre-
treatment with IFNβ. At the end of a 6-h migration period, 
cells that had translocated through the membrane were 
counted (Fig.  4d). NCC treated with IFNβ for the period 
from 0 to 48  h showed a significant reduction of their 
capacity to migrate through the membrane. NCC treated 
only during the last 6 h of the migration period (42–48 h) 
were not impaired (Fig. 4e). This set of data suggests that 
(1) the migration inhibition by IFNβ can also be measured 
in a different (here 3-dimensional) test setup; and (2) that 
cells must be exposed for >6 h to IFNβ for the inhibition of 
migration to become apparent.
Transcriptome changes and alterations 
of superordinate biological processes induced by IFNβ 
in NCC
To obtain more data on the type of effects IFNβ has on 
NCC, cells were exposed for 48  h to the cytokine (500 
pM). Then, mRNA was prepared from five different cell 
lots and used for gene expression analysis by Affymetrix 
microarray technology. The data were compared to those 
obtained for seven toxicants and pharmaceuticals (arse-
nic trioxide, cyproconazole, PBDE-99, triadimefon, TSA, 
VPA, and geldanamycin) known to inhibit the migration of 
NCC (Zimmer et  al. 2014; Pallocca et  al. 2016). Each of 
the compounds was used at its respective highest non-cyto-
toxic concentration, and the data structure was visualized 
by a principal component analysis (Fig. 5a). Plotting of the 
first two principal components showed a strong separation 
between IFNβ-treated samples and all other samples along 
the first principal component axis. This was due to the 
much stronger gene regulation response triggered by IFNβ, 
compared to small molecular weight toxicants.
The gene expression data were then used to determine 
the differentially expressed genes (DEG). The DEG for 
each toxicant were defined here as the group of microar-
ray probe sets (PS), which differed significantly from nega-
tive controls (FDR adjusted p value ≤0.05), and showed 
expression level changes (fold change (FC)) of ≥1.8 or 
Fig. 3  Maintenance of basic NCC functions and morphology in the 
presence of IFNβ. a NCC were treated with IFNβ (500 pM) or sol-
vent (Ctrl) for 48  h, allowed to migrate in the last 6  h of the treat-
ment period, and finally fixed for immunofluorescence staining. The 
microfilament cytoskeleton was visualized by phalloidin; antibodies 
to TOM20 were used to visualize mitochondria and anti-GM130 for 
the Golgi apparatus. b NCC were seeded for 0, 6, and 24 h (adhesion 
time) in culture medium supplemented with IFNβ (500 pM) or sol-
vent. Then, cells were lysed and the amount of phosphorylated FAK 
was measured by Western blot analysis. The mean intensity of each 
band normalized to the respective loading control (GAPDH) ± SD is 
reported below each condition (n = 3). In the control (0 h = non-adher-
ent cells), no band was detected. No significant change was observed 
between control and treatments at 6 and 24 h. c NCC were exposed 
to a cytokine mix (CM, 10 ng/ml TNFα, and 10 ng/ml IL1β), IFNβ 
(500 pM) or a combination of both for 1  h. Cells were then fixed 
and stained for nuclear factor kB (NFkB, green). Representative pic-
tures for each condition are shown, with nuclei counterstained with 
H-33342 (red). Nuclei with translocated NFkB appear yellow, instead 




≤0.55 (Falsig et al. 2004; Pallocca et al. 2016). IFNβ trig-
gered a much stronger up-regulation than down-regulation 
response, altering altogether 565 PS (Fig. 5b). To get more 
insight into the deregulated genes, the DEG were sorted 
according to their p values and the top 20 up- and down-
regulated genes were displayed. Among the most strongly 
up-regulated genes, there were many IFN-induced proteins 
(IFI), which have mostly roles in the inhibition of viral 
replication. Other genes were the 2′–5′ oligoadenylate syn-
thetase family (OAS1/2), which activates the latent RNase 
L, and induces viral RNA degradation; another typical 
biomarker of IFN anti-viral responses was the MX dynamin 
like GTPase (MX1). In addition, we found a strong up-
regulation of the chemokine response (CXCL10 and 11). 
The group of strongly down-regulated genes was more het-
erogeneous. It comprised, for instance, the TNF receptor 
superfamily member TNFRSD10D, argonaute 1 (AGO1, 
the catalytic component of the RISC complex involved in 
the RNA interference process), and the zinc-dependent 
metalloprotease tolloid-like (TLL2) (Fig. 5c).
As the analysis of individual genes did not directly indi-
cate which migration-related pathways may be impaired, 
Fig. 4  Confirmation of impaired NCC migration in the presence of 
IFNβ in secondary functional assays. a NCC were allowed to migrate 
for 48 h, and they were exposed to IFNβ at the indicated concentra-
tions for the entire migration period. Phase contrast images were 
taken every 15 min during the last 30 h of migration for cell tracking. 
b Representative migration tracks for the control and 500 pM IFNβ-
treated cells are shown. Tracks are normalized to the same starting 
point (blue circle); x and y dimensions are scaled similarly (see scale 
bar). c Averaged accumulated distance covered by the cells was then 
calculated for each test concentration. At least 10 cells were followed 
for each condition (= 1 technical replicate). The number of inde-
pendent replicates for each condition is reported in the graph. Error 
bars indicate standard deviations (SD). Statistics is based on t test 
analysis between control and maximal IFNβ concentration samples 
(**p ≤ 0.01); an ANOVA across all data, followed by Dunnet’s post-
hoc test yielded the same significance level for 500 pM IFNβ. d NCC 
pre-treated for 42 h with IFNβ or solvent were seeded into transwells. 
Then, the cells were induced to migrate through the transwell porous 
membrane by addition of 5% FBS into the lower chamber of the tran-
swell, in the presence of IFNβ (500 pM) or respective control. After 
additional 6 h in the presence or absence of IFNβ, migrated cells were 
stained with crystal violet. Four fields per replicate were imaged, and 
the cells were counted. e Quantification of the number of migrated 
cells for the different conditions: the total IFNβ exposure period is 
indicated; data are from four independent experiments. Error bars 
indicate standard deviations (SD). *p ≤ 0.05. (Color figure online)
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Fig. 5  Transcriptome changes triggered by IFNβ in NCC. Sampling 
for microarray analysis was performed in NCC after 48-h exposure 
to non-cytotoxic, but migration-inhibiting, concentrations of eight 
test battery hits, as identified in Zimmer et al. (2014). Data are from 
five independent experiments (= data points of one colour, but differ-
ent shapes). a Principal component analysis (PCA) was performed, 
and a 2D plot was generated to display the transcriptome data struc-
ture across compounds and experimental replicates. The positions of 
IFNβ-exposed samples, and the respective control, are circled. On 
the axes, the first two principal components are plotted, and the per-
centage of covered variances is reported. b Number of differentially 
up-regulated (UP) or down-regulated (DOWN) genes (DEG, IFNβ 
vs control) and the corresponding biological processes (over-repre-
sented GO classes) was identified. Over-represented KEGG path-
ways were searched amongst all DEG (UP and DOWN), and the only 
two significant pathways are indicated. c Identified DEG were sorted 
according to their p value. The top 20 up- (yellow) and down- (blue) 
regulated genes are shown as bar graphs indicating the fold change 
(FC). Large regulation factors were observed especially for genes that 
showed very low expression in untreated cells (as is common for tran-
scriptome analysis of inflammatory situations). The effect is unlikely 
to be due to baseline variations, as the sorting was done according 
to the p value for the regulation. d Ring diagrams show the relative 
distribution of 6 superordinate biological processes (IFN response, 
migration/chemotaxis, apoptosis, signaling, differentiation, and other) 
amongst the over-represented GO classes (upper ring) and the num-
ber of the different signaling-related over-represented GO classes 
(lower ring). Genes with a central role in the JAK-STAT pathway are 
depicted in bold. (Color figure online)
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we investigated whether biologically linked groups of genes 
were co-ordinately regulated. More than 500 gene ontol-
ogy (GO) terms were enriched (adjusted p value ≤0.05) 
amongst the up-regulated genes, while only 24 terms were 
over-represented amongst the down-regulated genes. To 
get a better idea on co-ordinately affected pathways, we 
also identified over-represented KEGG pathways amongst 
the sum of DEG. The two pathways found by this approach 
were “antigen processing and presentation” (15 genes rep-
resented) and the “cytokine-cytokine receptor interaction” 
pathway (17 genes represented). This was not surpris-
ing, given a main role of interferons in these processes 
(Fig. 5b), but it did not offer an evident explanation, why 
migration was impaired.
To get an overview of the over-represented GO groups, 
we assigned them to six superordinate cell biological pro-
cesses (Waldmann et  al. 2014): IFN responses, migra-
tion, apoptosis, signaling, differentiation, and others. As 
expected, most of the enriched GO classes belonged to the 
“IFN response group” (230 GO term groups). We focused 
on the signaling-related over-represented GO terms (40 
groups) to get some hints regarding the mode of action of 
IFNβ on the migration capacity of NCC. Several GO in 
this group related to innate immunity and inflammatory 
signaling. Amongst the more general signal transduction 
pathways, only the JAK-STAT pathway was clearly over-
represented (4 GO groups) with several key players of this 
pathway being up-regulated (Fig. 5d). For this reason, we 
decided to examine the role of JAK-STAT signaling on 
NCC migration more directly.
Correlation of IFNβ-induced inhibition of NCC 
migration and JAK-STAT pathway activation
As readout for JAK-STAT activation, we chose to analyze 
the phosphorylation level of one of the members of the 
STAT family, STAT1. This step is necessary for the het-
erodimerization of STAT proteins, which together with 
IRF9 form, and then the transcription factor IFN-stimu-
lated gene factor 3 (ISGF3), and promotes IFN-induced 
genes transcription. Western blot analysis showed an 
increase of p-STAT1 in NCC after stimulation with both 
IFN class I interferons, with IFNα being about 100-fold 
less potent than IFNβ (Fig. 6a, b). The extent of STAT1 
phosphorylation was quantified, and it correlated with 
the extent to which migration was inhibited. This data 
set showed clearly that p-STAT1 levels correlated with 
the inhibition of migration in the case of IFNβ treat-
ment (Fig. 6c). To reach 50% of STAT1 phosphorylation, 
NCC needed to be exposed to 2 nM of IFNα (vs 5 pM 
IFNβ), but also for IFNα, the increase of pSTAT1 cor-
related with inhibition of migration (Fig. 6d). To evaluate 
a specific role of JAK-STAT signaling, we also examined 
phosphorylation of extracellular signal regulated kinases 
Fig. 6  Correlation between JAK-STAT pathway activation and inhi-
bition of NCC migration upon treatment with class I IFN. a, b NCC 
were exposed to the indicated concentrations of IFNβ and IFNα for 
1 h. Then, cells were harvested and protein samples were prepared. 
The amount of phosphorylated STAT1 (p-Tyr701) was measured 
by western blot analysis (representative blots are shown). c, d Band 
intensity was quantified and normalized to the respective GAPDH 
antibody band. For better comparison, the migration inhibition data 
from Fig. 1b are shown in black in the same graph. Data are means 
from three independent experiments. Error bars indicate standard 
deviations (SD). Statistical analysis was based on ANOVA, followed 
by Dunnet’s post-hoc test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001)
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(ERK1/2), of protein kinase B (AKT), and of glyco-
gen synthase kinase-3β (GSK3β), but none of them was 
changed by exposure to IFNβ (suppl. Fig. S6).
To obtain more causal evidence for the role of the JAK-
STAT pathway in the inhibition of NCC inhibition, we used 
two different and specific JAK inhibitors (ruxolitinib and 
tofacitinib) to block the kinase signaling. Both inhibitors 
blocked STAT1 phosphorylation concentration-depend-
ently (Fig. 7a, b). Moreover, exposure to ruxolitinib com-
pletely abolished the activation of eight different interferon 
target genes in cells exposed to IFNβ (Fig. 7c). A pharma-
cological block by any of the two inhibitors of the pathway 
resulted in the complete prevention of adverse effects of 
IFNβ. Moreover, the extent of signaling pathway inhibition 
correlated significantly (p < 0.01) with the rate of reversal 
of the intereferon-beta effect (Fig. 7d, e).
Requirement for continued JAK-STAT signaling 
for impairment of NCC migration
Having established that the adverse effects of IFNβ on the 
migration of NCC are signaled via the JAK-STAT pathway, 
we were interested in the role of short vs continued expo-
sure to interferons. To address this question, we exploited 
the rescuing effect of the JAK inihibitor ruxolitinib to ter-
minate the IFNβ signaling at defined time points.
The standard migration assay, as described in 3.1, 
was performed in the presence of IFNβ (or respective 
Fig. 7  Abolishment of the effect of IFNβ on NCC migration by inhi-
bition of the JAK-STAT pathway. a, b NCC were pre-treated for 0.5 h 
with two different JAK inhibitors (ruxolitinib and tofacitinib) at the 
indicated concentrations. Then, the cells were further treated for 1 h 
with the inhibitors in cell culture medium supplemented with 500 pM 
IFNβ. Finally, cells were harvested and the amount of phosphoryl-
ated STAT1 (p-STAT1) was measured by western blot analysis (rep-
resentative blots are shown). c NCC were exposed to IFNβ for 48 h at 
the indicated concentrations, either with or without ruxolitinib (Rux, 
10  µM). Then, cells were harvested, and total RNA was extracted 
and retro-transcribed. Effects on selected mRNAs were evaluated by 
qPCR. Expression levels were normalized against the housekeeping 
gene, GAPDH and are expressed relative to control levels (untreated 
cells). The mRNA expression in the presence of Rux is shown in red. 
Note that the red symbols are often overlapping, due to complete 
inhibition down to control levels. d, e Band intensities were quanti-
fied for p-STAT1 (normalized to GAPDH). In a parallel set of experi-
ments, migration (after 48 h) was evaluated in the presence of IFNβ 
(500 pM) plus ruxolitinib (left) or tofacitinib (right). Data are from 
three independent experiments. Error bars indicate standard devia-
tions (SD). Statistics was performed by ANOVA, followed by Dun-




control). Ruxolitinib was added to the cells immediately 
or at various time points after exposure to interferon. The 
inhibition of migration was then evaluated at 48 h for var-
ious experimental conditions (Fig. 8a). The results from 
these experiments showed that the inhibition of migra-
tion (by IFNβ) was rescued when the inhibitor ruxolitinib 
was added not later than 6 h after the beginning of IFNβ 
treatment. When ruxolitinib was added after 10  h (or 
later), inhibition of migration (by at least 25%) occurred 
(Fig. 8b). Thus, inhibition of migration by IFNβ required 
receptor signaling for at least 6–10 h, while activation of 
the JAK-STAT pathway for up to 6 h hardly affected the 
migration capacity of NCC (Fig. 8b).
This finding was corroborated when standard migra-
tion assays were performed and IFNβ was washed out 
after 3  h. Under these conditions, no inhibition of cell 
migration was observed (data not shown).
Discussion
In the present study, a potential developmental toxicity 
hazard of IFNβ with regard to NCC disturbance was con-
firmed. Migration of NCC was affected at low pM con-
centrations by IFNβ, while IFNα was substantially (two 
orders of magnitude) less potent, and IFNγ did not affect 
migration in the pM range. The effect on migration clearly 
differed from the cytostatic activity of the cytokines, as 
(1) IFNβ and IFNα had similar cytostatic potency on the 
test system, and (2) as cytostatic and migration-inhibiting 
properties could be experimentally separated. Moreover, 
the specific effect of IFNβ on migration was confirmed 
in assays with different protocols and endpoints. A closer 
cell biological characterization showed that the inhibition 
of migration correlated well with a prolonged activation of 
the JAK-STAT signaling pathway in various sets of experi-
ments. Thus, prolonged activation of STAT1 by IFNβ in 
Fig. 8  Requirement for con-
tinued JAK-STAT signaling to 
NCC migration impairment. a 
NCC were allowed to migrate 
for 48 h. During this time, they 
were exposed to IFNβ while 
ruxolitinib (10 µM) was added 
to the culture medium at differ-
ent time points after the start of 
the migration. The percentage 
of migrated cells was quantified 
for all conditions after 48 h. 
Migration was inhibited ≥25% 
in all conditions denoted in 
blue. Ruxolitinib without IFNβ 
had no effect on migration. b 
Graphical representation of the 
effects of IFNβ and JAK-STAT 
pathway-inhibitors on the 
transcription of target genes and 
on the functionality of NCC. 
NCC migration was unimpaired 
in the absence of IFNβ or when 
IFNβ was present together with 
ruxolitinib. NCC migration was 
impaired when IFNβ was pre-
sent alone, or when ruxolitinib 




NCC provides a biochemical marker of potentially adverse 
effects of IFNβ on fetal development during pharmacologi-
cal use.
As IFNα and IFNβ signal through the same recep-
tor complex, the largely different potencies observed here 
may appear surprising. However, such observations are 
explained by the higher affinity of IFNβ (compared to 
IFNα) for the shared receptor subunits. A more pronounced 
effect of IFNβ has also been observed in other test systems. 
For instance, only IFNβ induced JAK1 activation in human 
myocardial fibroblasts, and this was associated with a 120-
fold higher potency to trigger an anti-viral response (vs 
IFNα) (Heim et  al. 1996; Grumbach et  al. 1999); also in 
human vascular endothelial cells, a 2–3 log difference was 
observed for IFNβ vs IFNα in functional assays (da Silva 
et al. 2002), and IFNβ was 100-fold more potent than IFNα 
with respect to the inhibition of differentiation of human 
monocytes into osteoclasts (Coelho et  al. 2005). Notably, 
the difference in affinity is only relevant for the biologi-
cal effect in cells that express low numbers of receptors; 
in cells with a high receptor reserve, functional effects are 
observed for both type I interferons within the same con-
centration range (van Boxel-Dezaire et  al. 2006; Moraga 
et al. 2009; Schreiber and Piehler 2015). As high and low 
receptor numbers are not an absolute measure, but relate to 
the percentage of receptors required to trigger a full bio-
logical response in a given cell type, the potency difference 
of IFNα and IFNβ may differ for different responses within 
one given cell (Zula et al. 2011; Piehler et al. 2012). From 
these considerations, widely accepted in the interferon lit-
erature, we conclude that NCC express low numbers of 
the receptor subunits IFNAR1 and IFNAR2 on their sur-
face. Moreover, we may conclude that a higher occupancy 
is required to affect migration than to trigger a cytostatic 
effect.
To our knowledge, effects of IFNβ on the migration of 
neural cells or their precursors have not been reported yet. 
However, the migration and invasion properties of glioma 
cells are affected by interferon-regulated genes (Yu et  al. 
2011; Tarassishin and Lee 2013) and neuronal survival 
seems to require a basic level of interferon signaling (Ejler-
skov et  al. 2015). Moreover, interference of IFNβ with 
migration has been shown especially in the leukocyte line-
age of cells (Lou et al. 1999; Staun-Ram and Miller 2011; 
Floris et al. 2002) and for various tumor cells (Booy et al. 
2015; Rossi et al. 2015). Many of these studies suggest that 
cell migration may be affected by interferons through a 
reduced secretion of matrix metalloproteases (Stuve et  al. 
1997; Yen et al. 2010). This mechanism is unlikely to play 
a role in the experimental systems used in our study, as the 
penetration of extracellular matrix is not required for two-
dimensional NCC migration. As IFNβ is extremely pleio-
tropic in its activities, great care is required to distinguish 
effects that are correlated with reduced migration and 
effects that causally lead to reduced migration.
In the present study, we found that JAK-STAT signaling 
is a causal factor involved in reduced migration. In paral-
lel, we invested major efforts to avoid erroneous conclu-
sions, based on secondary effects triggered by IFNβ. These 
experiments followed two main lines. First, we made sure 
that migration was specifically affected, and that test results 
were not an indirect consequence of the known cytostatic 
effects of interferons (Bekisz et  al. 2010). These precau-
tions are particularly important for slowly migrating cells 
(as NCC), while such controls are less common in the field 
of leukocyte migration. One taken approach was to run the 
assay under conditions that did not allow any proliferation 
(presence of a mitosis inhibitor). IFNβ showed its effect 
on migration also in this setup. The second approach was 
to use an assay with a faster readout (transwell assay), and 
then, going one step further, we followed individual cell 
migration directly by tracking. In addition, these experi-
ments confirmed the inhibition of migration in a low pM 
range of IFNβ.
Second, we provided evidence that IFNβ treatment did 
not obviously alter the cell differentiation state. In theory, 
extracellular signals may lead to the differentiation of NCC 
to neurons or other progeny that are less prone to migration. 
This is unlikely to happen in our test system, as several 
differentiation markers remained unchanged, as a charac-
terization on the organellar level did not reveal differences 
after treatment with IFNβ, and as key molecules relevant 
to adhesion and migration, like focal adhesion kinase or 
expressed integrins, remained unaffected. The stability 
of the overall NCC phenotype is remarkable, especially 
in the light of the transcriptome analysis, which showed 
that a typical (anti-viral and immunomodulatory) inter-
feron response was triggered on the level of gene expres-
sion. Most conspicuous amongst these regulated transcripts 
were several chemokines and chemokine receptors (CCL5, 
CXCL10, CXCL11, and CCR1), but the changes were 
observed too late to be relevant for the effects on migra-
tion observed here. Moreover, the migration of NCC was 
not affected in our assay by chemokine receptor antagonists 
(not shown).
Several sets of data presented here suggest that the extent 
of activation of the JAK-STAT pathway correlates with 
inhibited migration by IFNβ. Moreover, we also explored 
the temporal relationship of this pathway activation with 
NCC motility. It is known that cytokines, like interferons, 
may either trigger a hit-and-run signaling response (Brask 
et  al. 2004), i.e., short formation of the receptor-ligand 
complex has long-acting or irreversible effects, or they 
may lead to an acute cellular change reversible after termi-
nation of cytokine–receptor interaction. In other cases of 
cytokine action, prolonged receptor signaling is required to 
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trigger downstream cellular processes, and once triggered 
the cellular alterations may remain stable. Here, we found 
an example of the latter response pattern: activation of the 
JAK-STAT pathway for less than 6  h had no significant 
effect on cell migration; activation for more than 10 h was 
sufficient to trigger the full response, also when the kinase 
pathway was then blocked by specific inhibitors. This sug-
gests that short peak levels of the cytokine would not affect 
NCC migration in a fetus, but if such levels are maintained 
in chronic infection, or after transfer of pharmacologi-
cally applied IFNβ across a compromised placental barrier, 
adverse developmental effects may follow.
In this context, it is important that interferons show a 
high degree of species-specificity. The evaluation of the 
effects of human IFNβ is, therefore, not possible in rodent 
or rabbit models, and only some monkeys (e.g., rhe-
sus monkeys) show pharmacodynamic responses to the 
cytokine. Concerning the pharmacokinetic behaviour, the 
most relevant data come from clinical trials. IFNβ is nor-
mally given to MS patients intramuscularly at a dose of 
6 million international unites (MIU) (Barbero et al. 2004). 
In controlled pharmacokinetic studies, 12 MIU IFNβ given 
intramuscularly to healthy patients led to a  Cmax of 44 IU/
ml, corresponding to ~9 pM (Alam et  al. 1997). A rough 
linear approximation would suggest that the clinical dose 
used in MS would lead to peak plasma levels of 4–5 pM, 
i.e., roughly within the range of the concentrations found to 
affect NCC here. In a previous study (Zimmer et al. 2014), 
we calculated the dose to result in developmental toxicity 
to monkeys (FDA 1999) to correspond to plasma levels of 
540 pM. This concentration is higher than the concentra-
tions found here to affect human NCC, but the data basis 
is relatively limited and the concentration estimate requires 
several assumptions for the PBPK modelling (Zimmer et al. 
2014). Unfortunately, retrospective clinical studies do not 
provide a clearer set of information. The safety of IFNβ 
in pregnancy has been observed on several occasions, but 
with contrasting results (Sandberg-Wollheim et  al. 2005). 
To date, women with MS are advised to interrupt the expo-
sure to the drug for precautionary reasons (Lu et al. 2012; 
Pozzilli and Pugliatti 2015), but information on no-effect 
levels or critical windows of susceptibility are not available.
In the absence of clear clinical data, and in the perti-
nent case of highly species-specific effects of the drug, 
our human cell-based testing approach allowed important 
insights into potential toxicological hazard, and into the 
concentration range at which this may be expected. In this 
context, it is important that the phenotypic adverse effect 
(inhibited migration) was consistent with a plausible bio-
chemical mechanism of IFNβ signaling (JAK kinase activa-
tion), that exact information on the relevant concentration 
range was obtained, and that several tests and endpoints 
confirmed the type of potential hazard identified in initial 
studies. On the basis of this example study, we suggest that 
a combination of cellular tests based on relevant human cell 
types and engineered tissue structures (e.g., placental bar-
rier) be used more frequently to obtain information on toxi-
cological properties of human-specific drugs.
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